Y-mAbs Therapeutics
YMAB
YMAB was delisted on the 15th of September, 2025.
88 hedge funds and large institutions have $266M invested in Y-mAbs Therapeutics in 2022 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 28 increasing their positions, 31 reducing their positions, and 24 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
10% less repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 31
1.08% less ownership
Funds ownership: 58.97% → 57.89% (-1.1%)
9% less funds holding
Funds holding: 97 → 88 (-9)
32% less capital invested
Capital invested by funds: $394M → $266M (-$128M)
38% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 24
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
+$15.4M |
| 2 |
AllianceBernstein
Nashville,
Tennessee
|
+$10.5M |
| 3 |
State Street
Boston,
Massachusetts
|
+$8.75M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$4.56M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$3.25M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Artisan Partners
Milwaukee,
Wisconsin
|
-$25.6M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$24.2M |
| 3 |
LGM
Logos Global Management
San Francisco,
California
|
-$4.05M |
| 4 |
New York State Common Retirement Fund
Albany,
New York
|
-$2.17M |
| 5 |
LOAMS
Lombard Odier Asset Management (Switzerland)
Petit-Lancy,
Switzerland
|
-$1.68M |
YMAB Hedge Fund Activity: Q1 2022 in Review
88 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in Y-mAbs Therapeutics (YMAB) for Q1 2022, worth a combined $266M — down 32% from $394M a quarter earlier.
Sellers outnumbered buyers: 24 funds closed out of YMAB and 15 opened new positions — a net loss of 9 holders — while 31 trimmed existing stakes and 28 added.
The largest buyer was Polar Capital Holdings, adding an estimated $15.4M. The largest seller was Artisan Partners, exiting entirely with an estimated $25.6M sold.
- 88 institutional investors held Y-mAbs Therapeutics (YMAB) as of Q1 2022, down from 97 in Q4 2021.
- Funds reported $266M of Y-mAbs Therapeutics stock for Q1 2022, down 32% quarter-over-quarter.
- 15 funds opened new Y-mAbs Therapeutics positions in Q1 2022 and 24 closed out, a net change of -9 holders.
- The largest Y-mAbs Therapeutics buyer in Q1 2022 was Polar Capital Holdings, an estimated $15.4M added.
- The largest Y-mAbs Therapeutics seller in Q1 2022 was Artisan Partners, an estimated $25.6M sold.
Based on aggregated 13F filings for Q1 2022.